B7-33 vs Telmisartan
A side-by-side research comparison of B7-33 and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | Telmisartan |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | FDA-approved drug |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | ~3.3 kDa | 514.62 Da |
| Half-life | Short (peptide) | ~24 hours |
| Bioavailability | Injection (research) | ~42-58% oral |
| Typical dose | Not established for humans | 20-80 mg per day |
| Frequency | Research only | Once daily |
| Route | Injection (research) | Oral tablet |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.